PetVivo Holdings, Inc. (OTCQX: PETV) (OTCID: PETVW) will present at the Life Sciences Investor Forum on June 24, 2026, providing investors with insights into its medical device and therapeutic solutions for animals. Chief Executive Officer John Lai is scheduled to deliver the presentation during the live, interactive online forum hosted by VirtualInvestorConferences.com. The event offers a platform for investors and industry professionals to engage directly with management in real time.

The presentation is set to begin at 12:00pm ET on June 24, 2026. A replay of the webcast will be made available following the conclusion of the conference. Additionally, the company has opened a window for one-on-one meetings, which will be available from June 24, 2026, through June 30, 2026. Investors are encouraged to pre-register and perform a system check to ensure smooth participation.

PetVivo focuses on veterinary medical technology, with its flagship product being Spryng with OsteoCushion Technology. This veterinarian-administered intra-articular injection is designed to restore joint mechanics and manage conditions such as lameness and osteoarthritis in dogs, cats, and horses. The company continues to expand its commercialization efforts and international distribution initiatives.

Recent developments for PetVivo include Health Canada's recognition of Spryng as a veterinary medical device and the launch of PetVivo AI initiatives. The company leverages a portfolio of twelve patents and six trade secrets to protect its biomaterials and production processes. Its product pipeline also includes PrecisePRP, an off-the-shelf platelet-rich plasma product for veterinarians.

Virtual Investor Conferences (VIC) specializes in providing interactive forums for publicly traded companies to present directly to investors. The platform replicates the components of an on-site investor conference, offering enhanced capabilities for connecting with retail and institutional investors globally.

PetVivo Holdings, Inc., in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., a leading provider of medical devices and biomedical therapeutics for equines and companion animals, has announced a virtual investor event titled "What Veterinarians Are Seeing and How Access Is Expanding." The event is scheduled for Tuesday, June 16, 2026, at 1 p.m. ET and is designed for both new and current investors.

Event Overview

The virtual event will provide attendees with an accessible overview of the company's business operations, with a particular focus on Spryng® with OsteoCushion® Technology, real-world veterinary field feedback, and PetVivo's ongoing initiatives to broaden market reach through sales and distribution relationships. The company expects the event to offer investors a firsthand look at how veterinarians are evaluating and using Spryng in clinical practice.

Featured Speakers

The moderator-led discussion will feature the following participants:

How to Attend

Investors can tune in to the live event through the following platforms:

• YouTube: https://www.youtube.com/live/QLFfsfCpE1U?si=ItU-PWgNUKsQ2tkQ
• LinkedIn: https://www.linkedin.com/events/7466155223904890880?viewAsMember=true

A replay of the event is expected to be available following the webcast. Investors can also visit the company's Investor Relations page at https://www.petvivo.com/investors for additional company information, financial materials, and updates.

About PetVivo Holdings, Inc.

PetVivo Holdings, Inc., in cooperation with its wholly-owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. The company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time-efficient manner, with an emphasis on the accelerated timeline to revenues for veterinary medical devices.

PetVivo maintains a robust pipeline of products for the treatment of animals and people, protected by a portfolio of twelve patents and six trade secrets covering its biomaterials, products, production processes, and methods of use. The company's lead products include:

• SPRYNG® with OsteoCushion® Technology — a veterinarian-administered, intra-articular injection for the management of lameness and other joint-related afflictions, including osteoarthritis, in cats, dogs, and horses
• PrecisePRP® — a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians

Both products are currently available for commercial sale.